Thursday, Oct 06, 2022
×
Outlook.com
×

Corbevax

Centre Approves Corbevax As Booster Covid-19 Dose For Vaccinated Adults

This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.   

10 August 2022

Vaccine.

COVID-19: NTAGI May Recommend Vaccination For 5-12 Age Group On Friday

Corbevax is currently being used to inoculate children against COVID-19 in the age group of 12 to 14 years.


Covid-19 jabs for children in the age group of 12-14 years from Wednesday.(File photo-Representation

Covid Jabs For 12-14 Age Group From Wednesday, No More Comorbidity Clause For Adults Above 60

Covid-19 vaccine to be administered to the 12-14 years age group would be Corbevax manufactured by Biological E. Limited, Hyderabad, the Union health ministry said.


Covid-19 vaccine for kids aged 5-12 years.(Representational image)

NTAGI Panel Recommends Use Of Covid-19 Vaccines Corbevax, Covaxin For Children Aged 5-12 Years

NTAGI's Standing Technical Sub-Committee (STSC), however, couldn’t arrive at a decision on introducing Corbevax and Covaxin in the vaccination programme.

08 July 2022

DCGI Grants EUA To Corbevax For Those Aged 5-12, Covaxin For 6-12 Age Group

The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2 last year.


Covid-19: Corbevax, Covovax Approval Brings Spotlight On India-US Collaboration

Covid-19: The India has approved the use of Corbevax and Covovax against the virus, while the anti-viral drug Molnupiravir has been given approval to be used in emergency situations.

29 December 2021

BE's COVID-19 Vaccine Corbevax Gets DCGI Nod As Heterologous Booster Dose

Biological E Limited's COVID-19 vaccine, Corbevax, becomes the first heterologous COVID-1 booster vaccine that has been approved by the Drug Controller General of India (DGCI) for emergency situations.

04 June 2022

Advertisement

Biological E Aims To Produce 100 Mn Doses/Month Of Corbevax From Feb 2022

Corbevax has completed two Phase III clinical trials involving more than 3000 subjects between the ages of 18 and 80 at 33 study sites across India.

28 December 2021

Advertisement
28 December 2021
Covid-19 Vaccines: Expert Panel Recommends EUA For Covovax, Corbevax & Molnupiravir Pills

Covid-19 Vaccines: Expert Panel Recommends EUA For Covovax, Corbevax & Molnupiravir Pills

All the recommendations of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) have been sent to the Drugs Controller...


03 September 2021
Biological E's Corbevax Gets DCGI Approval For Phase 2/3 Clinical Trial  On Children, Adolescents

Biological E's Corbevax Gets DCGI Approval For Phase 2/3 Clinical Trial On Children, Adolescents

Mahima Datla, Managing Director, Biological E. Limited, said these approvals would help support its subsequent filings with the World Health Organization (WHO)...


Advertisement
Advertisement
Advertisement
Advertisement
Advertisement